Drug
Apraclonidine Ophthalmic
Apraclonidine Ophthalmic: highest development phase Phase 3, developed by Alcon Research. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Alcon Research
Trials
| Drug | Phase | Indication |
|---|---|---|
| Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free NCT07578363 | Phase 3 | Ocular Hyperemia |
Latest
No recent events.
Follow Apraclonidine Ophthalmic on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.